Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intoleranceHagop M. Kantarjian, Philipp le Coutre|Blood|2007Cited by 744
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P. Hughes, Dong‐Wook Kim, Jörge E. Cortes et al.|New England Journal of Medicine|2019Cited by 464
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptorMatthias Holdhoff, Philipp le Coutre|Blood Cells Molecules and Diseases|2005Cited by 81